Provided by Tiger Trade Technology Pte. Ltd.

Nextcure Inc.

11.10
+0.01000.09%
Post-market: 11.09-0.0100-0.09%17:50 EST
Volume:4.38K
Turnover:49.22K
Market Cap:38.91M
PE:-0.47
High:11.40
Open:11.30
Low:11.10
Close:11.09
52wk High:15.74
52wk Low:2.69
Shares:3.51M
Float Shares:2.53M
Volume Ratio:0.11
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-23.8671
EPS(LYR):-23.8819
ROE:-116.91%
ROA:-58.01%
PB:1.65
PE(LYR):-0.46

Loading ...

NextCure Advances SIM0505 and LNCB74 ADCs in Phase 1 Cancer Trials

Reuters
·
Jan 26

NextCure Inc. Highlights Targeted Cancer Therapy and Clinical Pipeline in New Presentation

Reuters
·
Jan 23

BRIEF-Nextcure Provides Business Update

Reuters
·
Jan 23

NextCure Inc - Expects Funds to Last Into First Half of 2027

THOMSON REUTERS
·
Jan 23

NextCure Inc - Sim0505 Phase 1 Data Update Expected in Q2 2026

THOMSON REUTERS
·
Jan 23

NextCure Provides Business Update

THOMSON REUTERS
·
Jan 23

NextCure files to sell 2.52M shares of common stock for holders

TIPRANKS
·
Nov 27, 2025

BRIEF-NextCure Files For Offering Of Up To 2.52 Million Shares Of Common Stock By Selling Stockholders - SEC Filing

Reuters
·
Nov 27, 2025

NextCure announces closing of $21.5M PIPE financing

TIPRANKS
·
Nov 17, 2025

NextCure Raises $21.5 Million in PIPE Financing

Reuters
·
Nov 17, 2025

Press Release: NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts

Dow Jones
·
Nov 17, 2025

NextCure Raises $21.5 Million in Private Placement of Common Stock

Reuters
·
Nov 12, 2025

NextCure Inc - Proceeds to Extend Cash Runway Into First Half of 2027

THOMSON REUTERS
·
Nov 12, 2025

Press Release: NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules

Dow Jones
·
Nov 12, 2025

NextCure Raised to Buy From Neutral by Ladenburg Thalmann

Dow Jones
·
Nov 07, 2025

Biopharmaceutical firm NextCure Q3 net loss narrows

Reuters
·
Nov 06, 2025

NextCure Inc. Highlights Progress in Targeted Cancer Therapies and ADC Trials in New Presentation

Reuters
·
Nov 06, 2025

NextCure Inc expected to post a loss of $3.98 a share - Earnings Preview

Reuters
·
Nov 03, 2025

NextCure Inc. Releases Corporate Presentation Highlighting Progress of Targeted Cancer Therapies and Ongoing Clinical Trials

Reuters
·
Oct 16, 2025

BRIEF-NextCure And Simcere Zaiming Announce Expansion Of Ongoing Phase 1 Trial Of SIM0505 Into The US

Reuters
·
Oct 16, 2025